+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Schizophrenia Therapeutics Market by Therapeutic Class (Second Generation, Third Generation), Administration (Injectable, Oral), Distribution Channel - Forecast 2024-2030

  • PDF Icon

    Report

  • 192 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5889558
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Schizophrenia Therapeutics Market size was estimated at USD 7.89 billion in 2023, USD 8.08 billion in 2024, and is expected to grow at a CAGR of 4.94% to reach USD 11.06 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Schizophrenia Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Schizophrenia Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Schizophrenia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Acadia Pharmaceuticals Inc., Alkermes Plc, Allergan Plc by AbbVie Inc., Amneal Pharmaceuticals, LLC, Astellas Pharma Inc., AstraZeneca plc, BioXcel Therapeutics, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb and Company, Delpor, Inc., Eli Lilly and Company, Gedeon Richter Plc, Johnson & Johnson Services, Inc., Karuna Therapeutics Inc, Lundbeck A/S, Luye Pharma Group Ltd, Lyndra Therapeutics Inc, Meiji Holdings Co., Ltd., Neurocrine Biosciences, Inc., Otsuka America Pharmaceutical Inc., Pfizer Inc., Reviva Pharmaceuticals Holdings, Inc., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, and Vanda Pharmaceuticals Inc.

Market Segmentation & Coverage

This research report categorizes the Schizophrenia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Therapeutic Class
    • Second Generation
    • Third Generation
  • Administration
    • Injectable
    • Oral
  • Distribution Channel
    • Hospital
    • Pharmacies
      • Offline
      • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Schizophrenia Therapeutics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Schizophrenia Therapeutics Market?
  3. What are the technology trends and regulatory frameworks in the Schizophrenia Therapeutics Market?
  4. What is the market share of the leading vendors in the Schizophrenia Therapeutics Market?
  5. Which modes and strategic moves are suitable for entering the Schizophrenia Therapeutics Market?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Schizophrenia Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of schizophrenia disorder among individuals worldwide
5.1.1.2. Government initiatives and campaigns to raise awareness regarding mental health conditions
5.1.1.3. Ongoing research for the development of efficient drugs for schizophrenia
5.1.2. Restraints
5.1.2.1. High cost of treatment and lack of insurance coverage
5.1.3. Opportunities
5.1.3.1. Increasing focus on personalized medicine for improving drug efficacy in patients with schizophrenia disorder
5.1.3.2. Advancements in schizophrenia treatment and therapeutics
5.1.4. Challenges
5.1.4.1. Side effects associated with the medications prescribed for schizophrenia
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Schizophrenia Therapeutics Market, by Therapeutic Class
6.1. Introduction
6.2. Second Generation
6.3. Third Generation
7. Schizophrenia Therapeutics Market, by Administration
7.1. Introduction
7.2. Injectable
7.3. Oral
8. Schizophrenia Therapeutics Market, by Distribution Channel
8.1. Introduction
8.2. Hospital
8.3. Pharmacies
8.4.1. Offline
8.4.2. Online
9. Americas Schizophrenia Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Schizophrenia Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Schizophrenia Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Acadia Pharmaceuticals Inc.
13.1.2. Alkermes Plc
13.1.3. Allergan Plc by AbbVie Inc.
13.1.4. Amneal Pharmaceuticals, LLC
13.1.5. Astellas Pharma Inc.
13.1.6. AstraZeneca plc
13.1.7. BioXcel Therapeutics, Inc.
13.1.8. Boehringer Ingelheim International GmbH
13.1.9. Bristol-Myers Squibb and Company
13.1.10. Delpor, Inc.
13.1.11. Eli Lilly and Company
13.1.12. Gedeon Richter Plc
13.1.13. Johnson & Johnson Services, Inc.
13.1.14. Karuna Therapeutics Inc
13.1.15. Lundbeck A/S
13.1.16. Luye Pharma Group Ltd
13.1.17. Lyndra Therapeutics Inc
13.1.18. Meiji Holdings Co., Ltd.
13.1.19. Neurocrine Biosciences, Inc.
13.1.20. Otsuka America Pharmaceutical Inc.
13.1.21. Pfizer Inc.
13.1.22. Reviva Pharmaceuticals Holdings, Inc.
13.1.23. Sumitomo Dainippon Pharma Co., Ltd.
13.1.24. Takeda Pharmaceutical Company Limited
13.1.25. Vanda Pharmaceuticals Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. SCHIZOPHRENIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. SCHIZOPHRENIA THERAPEUTICS MARKET DYNAMICS
FIGURE 7. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
FIGURE 8. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 6. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 9. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 12. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 15. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 30. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 31. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 34. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 35. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 49. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 52. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 53. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 56. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 57. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 60. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 61. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 64. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 65. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 68. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 69. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 72. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 73. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 76. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 77. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 80. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 81. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 84. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 85. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 88. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 89. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 92. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 93. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 101. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 102. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 105. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 106. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 109. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 110. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 113. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 114. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 117. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 118. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 121. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 122. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 125. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 126. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 129. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 130. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 133. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 134. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 137. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 138. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 141. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 142. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 145. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 146. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 161. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 162. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 165. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 166. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 169. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 170. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 173. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 174. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 185. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 186. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 187. SCHIZOPHRENIA THERAPEUTICS MARKET LICENSE & PRICING

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Acadia Pharmaceuticals Inc.
  • Alkermes Plc
  • Allergan Plc by AbbVie Inc.
  • Amneal Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BioXcel Therapeutics, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb and Company
  • Delpor, Inc.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • Johnson & Johnson Services, Inc.
  • Karuna Therapeutics Inc
  • Lundbeck A/S
  • Luye Pharma Group Ltd
  • Lyndra Therapeutics Inc
  • Meiji Holdings Co., Ltd.
  • Neurocrine Biosciences, Inc.
  • Otsuka America Pharmaceutical Inc.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Holdings, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vanda Pharmaceuticals Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 8.08 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.06 Billion
Compound Annual Growth Rate4.9%
Regions CoveredGlobal

Related Topics

Related Reports

Schizophrenia Therapeutics - Global Strategic Business Report - Product Image

Schizophrenia Therapeutics - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Antipsychotic Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Antipsychotic Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Antipsychotic Drugs - Global Strategic Business Report - Product Image

Antipsychotic Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Schizophrenia Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Schizophrenia Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 178 Pages
  • Global
From

About the Schizophrenia Drugs Market

The Schizophrenia Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of medications used to treat schizophrenia. Schizophrenia is a mental disorder characterized by abnormal social behavior and failure to recognize what is real. Common symptoms include delusions, hallucinations, disorganized speech, and disorganized behavior. The Schizophrenia Drugs market is composed of a variety of companies, including large pharmaceutical companies, small biotech firms, and generic drug manufacturers. These companies develop and market medications that are used to treat schizophrenia, such as antipsychotics, antidepressants, and mood stabilizers. Many of these medications are available in both generic and brand-name forms. Some of the major companies in the Schizophrenia Drugs market include Johnson & Johnson, Pfizer, Eli Lilly, Novartis, and AstraZeneca. These companies have developed a range of medications to treat schizophrenia, including Abilify, Seroquel, Zyprexa, and Risperdal. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.